Bioequivalence Study of Modified-Release Gliclazide Tablets in Healthy Volunteers

Table 3

90% Confidence intervals of 𝐶max, AUC0−𝑡, and AUC0−∞ of the test product compared to the reference product under fasted and fed conditions.

Pharmacokinetic parameter	90% Confidence interval
	Fasted condition	Fed condition
𝐶max	1.03–1.24	1.02–1.17
AUC0−𝑡	1.01–1.17	0.91–1.08
AUC0−∞	1.01–1.17	0.89–1.08

Bioequivalence interpretation requires the 90% confidence intervals to be within the acceptance criteria of 0.8–1.25.